Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma鈥檚 ambitious pipeline touches dozens of rare genetic diseases, which means each SEC document is dense with trial data, cash-runway tables and licensing terms. If you have ever typed 鈥淏ridgeBio Pharma SEC filings explained simply鈥� or hunted through a 200-page report for one orphan-drug update, you know how time-consuming it can be.
Stock Titan solves that problem. Our AI engine turns the company鈥檚 most complex disclosures into plain-language insights. Open a BridgeBio Pharma annual report 10-K simplified or drill into a BridgeBio Pharma quarterly earnings report 10-Q filing鈥攌ey figures, pipeline timelines and risk factors are highlighted automatically. Material news drops? A BridgeBio Pharma 8-K material events explained alert lands in your dashboard within seconds. Need trading color? We stream BridgeBio Pharma Form 4 insider transactions real-time so you never miss executive stock moves.
Here鈥檚 what you can uncover in seconds:
- Cash usage trends and dilution impact through BridgeBio Pharma earnings report filing analysis.
- Pipeline milestones linked to specific clinical programs, flagged across multiple forms.
- BridgeBio Pharma executive stock transactions Form 4 and broader insider trading Form 4 transactions for sentiment checks.
- BridgeBio Pharma proxy statement executive compensation details, including option grants and performance metrics.
Whether you鈥檙e understanding BridgeBio Pharma SEC documents with AI for the first time or monitoring seasoned positions, every filing type鈥�10-K, 10-Q, 8-K, S-1, SC 13D and more鈥攗pdates in real time from EDGAR. Spend less time scrolling and more time acting on the genetic-medicine data that moves the market.
Form 144 summary for BridgeBio Pharma, Inc. (BBIO)
This Form 144 reports an insider sale on 08/05/2025: 17,167 common shares sold through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) with an aggregate market value of $841,183.00. The filing lists 189,880,720 shares outstanding. The securities were acquired and paid for on 08/05/2025 via a stock option exercise from the issuer with cash payment. The filer reports "Nothing to Report" for securities sold in the past three months.
Note: Several filer and issuer contact fields in the form are blank in the provided text.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
